Fig. 8: Gain-of-function mutation in CREBBP mutant cells. | Nature Communications

Fig. 8: Gain-of-function mutation in CREBBP mutant cells.

From: Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function

Fig. 8

a–f Immunoblot (IB), histone acid extraction or immunoprecipitation (IP) for CBP, acetyl lysine, or BRCA1 was performed as indicated in the individual panels. a Global protein acetylation (IP acetyl lysine and IB for acetyl lysine), CBP autoacetylation (IP CBP and IB for acetyl lysine), and histone acetylation (acid extraction and IB) in HNSCC cell lines expressing wild-type CREBBP (HN31, Detroit 562) or CREBBP harboring a mutation in the TAZ2 domain (UM-SCC-22a, UM-SCC-17b). b CBP auto- and histone acetylation following treatment with A-485 in CREBBP mutant lines. c, d Global acetyl lysine and CBP autoacetylation (c), as well as histone acetylation (d) (densitometry below blot) in 293 T, HN31, and Detroit 562 cells forced to express either full-length CBP or a representative TAZ2 mutant CBP (Q1773X). e BRCA1 acetylation in HN31 cells forced to express full-length or TAZ2 mutant CBP and treated with A-485. f Total and acetyl CBP and BRCA1 in FaDu cells forced to express full-length or TAZ2 mutant CBP. g HR assay in either HN31 or FaDu cells forced to express full-length or TAZ2 mutant CBP. A minimum of three independent samples for each condition are shown and are presented as mean values +/− SEM. Two-sided p-values for each indicated comparison are derived from ANOVA with post hoc analysis adjusted for multiple comparisons.

Back to article page